Qufora lifts long-term goals despite supply challenges

The medtech firm, which provides solutions for people with chronic bowel disorders, had considerable 2021 topline growth, and is now adjusting its goals for the future.

Lena Lachenmeier, CEO of Qufora | Photo: Qufora / PR

Qufora, formerly known as MBH-International, has exited 2021 with significant advances on its top line.

According to the Danish medtech firm’s recently publicized full-year report, Qufora booked a DKK 125.2m (USD 17.7m) revenue in the now concluded year, equating to 20% growth compared to the preceding year.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs